Senti Biosciences Snags $53M For Gene Therapy
South San Francisco-based Senti Biosciences, a company developing gene- and cell-based therapies for challenging diseases, has raised $53M in a funding round, the company said on Tuesday. The funding was led by New Enterprise Associates, and also included 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital. Dr. Tim Lu is co-founder and CEO of Senti Biosciences.
posted on Tuesday, February 27, 2018 (Link to more information)
Related companies:
SENTI BIOSCIENCES, INC.
Related stories:
> Ambys Medicines Snags $140M
> Imago Biosciences Sees $26.5M
> Vineti Gets $13.75M For Pharmaceuticals Software
> Sangamo Therapeutics Acquires TxCell
> Gene Security Network Snags $12M More
silicontap.com Home